Eric Bhatt

Eric Bhatt has specialized in ESR1 ligand-binding domain mutations as acquired mechanisms of endocrine therapy resistance in metastatic HR+ breast cancer, investigating their clinical significance and therapeutic implications. His research has characterized the prevalence, dynamics, and functional consequences of ESR1 mutations detected in circulating tumor DNA from patients progressing on aromatase inhibitor therapy. He has contributed to clinical investigations of oral selective estrogen receptor degraders including elacestrant, which demonstrated efficacy in ESR1-mutated metastatic breast cancer as the EMERALD trial established. His translational work on serial ctDNA monitoring to track ESR1 mutation emergence and guide endocrine therapy sequencing has clinical implications for precision management of HR+ metastatic breast cancer.